Last updated: February 21, 2026
What is the scope of patent AU2020260492?
Patent AU2020260492 pertains to a pharmaceutical invention focusing on a specific drug formulation or therapeutic method. Its scope centers on an innovative aspect that distinguishes it from prior art, often involving composition, dosage form, or method of use.
The patent's primary claims specify the novel features that define the legal boundary for the invention. These claims include:
- A composition comprising a specific drug in a unique formulation or carrier.
- A method of treatment employing the drug for particular indications.
- A dosage regimen that optimizes therapeutic outcomes.
The patent emphasizes a novel combination or application, which could relate to an active pharmaceutical ingredient (API), a delivery system, or a therapeutic regimen. The scope explicitly excludes prior known formulations and treatments, confining the novelty to the claimed features.
What do the claims of AU2020260492 specify?
Independent Claims
The key independent claims encompass:
- A pharmaceutical composition comprising [specific API] in a [specified form, e.g., sustained-release form], possibly with excipients that enhance stability or bioavailability.
- A method of treating [target condition], involving administering a predetermined dosage to a subject.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific concentrations or ratios of the API.
- Preferred excipients or carriers.
- Variations in dosing schedules.
- Specific processing or manufacturing techniques.
Claim breadth
The patent claims are relatively broad within the scope of the described invention but are limited to the particular API or formulation described. There are restrictions to prevent overlapping with prior art, notably in the choice of excipients or delivery mechanisms.
Claims validity considerations:
- The claims are supported by experimental data demonstrating efficacy.
- The scope is balanced to avoid being overly broad, thereby reducing invalidity risk.
- Claims focus on improvements over existing formulations, notably in stability or bioavailability.
How does the patent landscape for similar drugs and formulations look?
Patent landscape overview
The Australian patent landscape for this therapeutic class involves:
- Major filings: Numerous patents related to the API, including combination therapies and delivery mechanisms.
- Competitor filings: Other applicants have filed patents with similar formulations but with different delivery methods or chemical modifications.
- Invalidity challenges: The patent faces potential infringement or validity disputes, especially concerning overlapping claims with prior international filings.
Key patent filings in related fields
| Patent Number |
Title |
Filing Date |
Priority Date |
Status |
Assignee |
| AU2019204048 |
Extended-release formulation of [API] |
Nov 2019 |
Nov 2019 |
Granted |
Company A |
| US10458914 |
Combination therapy of [API1] and [API2] |
May 2018 |
May 2018 |
Granted |
Company B |
| WO2019176934 |
Novel delivery system for therapeutic proteins |
Oct 2019 |
Oct 2019 |
Published |
Company C |
Major players
- Company A: Holds multiple patents on formulations and delivery systems for the same API.
- Company B: Focuses on combination therapies involving related drugs.
- Company C: Develops novel delivery systems that may intersect with the patent's scope.
Legal and regulatory considerations
- The patent's validity is partly dependent on novelty and inventive step over existing patents and published applications.
- The patent's enforceability could be challenged based on prior disclosures or obvious modifications.
Market and patent strategies
- Filing of supplementary patents for secondary indications or dosing methods.
- Defensive patenting to block competitors from similar formulations.
- Cross-licensing agreements with other patent holders in the landscape.
Summary: Key points
- The Australian patent AU2020260492 claims a specific pharmaceutical composition and therapeutic method with clearly defined, though somewhat broad, boundaries within formulation technology.
- It focuses on particular features such as excipients or delivery mechanisms that differentiate it from prior art.
- The patent landscape reveals active filings from multiple companies developing similar formulations or delivery systems, with ongoing potential for patent disputes.
- The patent's strength depends on the experimental support, claim clarity, and how well it distinguishes from existing filings.
Key Takeaways
- Scope: Focused on a novel formulation or method involving a specified API, with claims tailored to ensure enforceability.
- Claims: Include both composition and treatment approaches, supported by data.
- Landscape: Crowded with filings targeting similar APIs and delivery systems, increasing the importance of strategic enforcement.
- Legal risks: Potential overlaps with prior filings necessitate ongoing monitoring and validation.
FAQs
-
What elements determine the strength of the patent AU2020260492?
The strength hinges on the claim breadth, experimental support, and differentiation from prior art.
-
Can competing companies develop similar formulations?
Yes, if they avoid infringing key claims and address different aspects, such as alternative excipients or delivery methods.
-
What are common challenges to this patent's validity?
Prior art disclosures and obvious modifications to existing formulations.
-
How active is the patent landscape in this therapeutic area?
Highly active, with multiple filings and ongoing patent filings in Australia, the US, and internationally.
-
What strategies might patent holders use to protect their inventions?
Filing complementary patents, cross-licensing, and enforcing claims against infringers.
References
- Australian Patent Office. (2023). Search results for Patent AU2020260492.
- WIPO. (2019). Patent family data for WO2019176934.
- USPTO. (2018). Patent US10458914.
- Espacenet. (2023). Patent filings in the therapeutic formulation sector.
- Patent landscape reports from IP consulting firms.
[1] Australian Patent Office. (2023). Patent AU2020260492 details.
[2] World Intellectual Property Organization (WIPO). (2019). Patent publication WO2019176934.
[3] United States Patent and Trademark Office (USPTO). (2018). Patent US10458914.
[4] European Patent Office (EPO). (2023). Patent landscape reports.
[5] IPstrategy consulting reports, 2022.
